 |
 |
|||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
 |
 |
 |
 |
 |
|
|
|
 |
 |
|
|||||
 |
|
|||||||||||||||||||||||
 |
|
|||||||||||||||||||||||
|
Æterna Zentaris - Quebec City, Canada Having recently spun off its subsidiary Atrium Biotechnologies, Æterna Zentaris (AEZS) is emerging as a late-stage, pure play global biopharmaceutical company focused on endocrine therapy and oncology. Leading the class of LHRH antagonists with its Phase III candidate Cetrorelix, Æterna Zentaris is favorably poised to penetrate the $4 billion market for benign prostate hyperplasia (BPH). The company is also committed to advancing and expanding its product pipeline to penetrate other markets with unmet need such as prostate cancer, ovarian cancer and endometriosis. Æterna Zentaris' deep pipeline of established and breakthrough therapeutics allows it to optimize risk management while continuing to establish a leading position in research, development and manufacturing. Supported by an international network of scientific collaborators and an in-house drug discovery unit, Æterna Zentaris has the expertise to develop innovative therapies to market maturity. AEZS is traded on the NASDAQ and Canadian stock exchanges.
Accera, Inc. - Broomfield, CO Accera, Inc. is a privately held biotechnology company focused on the discovery and development of novel therapeutic products for neurodegenerative diseases. The company has developed a breakthrough approach for the treatment of Alzheimer's disease (AD) and other memory and cognition disorders based on its neuron energetics technology platform. The company's lead drug candidate, AC-1202, is a first-in-class molecule in Phase II clinical trials for AD and age associated memory impairment. Accera will develop AC-1202 and other small-molecule compounds in its pipeline with corporate partners for a range of memory and cognition disorders associated with neurological conditions and aging.
Lentigen Corporation - Baltimore, MD Lentigen Corporation is a privately owned biotechnology company focused on the manufacturing and development of lentiviral vectors using its proprietary gene delivery technology for a wide range of applications in biotechnology and medicine. Lentiviral vectors are highly adapted delivery vehicles that can transport genes or gene silencing sequences into cells with high efficiency and stability. Lentigen is positioning itself to become the leading provider of lentiviral vector products and services for academic, government, biotechnology and pharmaceutical researchers.
Sangart, Inc. - San Diego, CA Sangart is a privately held biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as alternatives to blood transfusions. Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1998. In the two decades prior to founding Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of oxygen transport by cell-free hemoglobin solutions, funded by competitive grants from the National Institutes of Health and the Department of Defense. From this experience, Sangart's lead product, Hemospan®, was designed using unique polyethylene glycol conjugation to create a hemoglobin-based product that is intended to serve as an alternative to donated blood. The key breakthroughs in the development of Hemospan were the understanding of the mechanisms of vasoconstriction and the development of simplified production methods that are designed to make the final product commercially viable. These breakthroughs laid the groundwork for Sangart's business concept of developing cost-effective oxygen carriers that can be used in lieu of transfused red blood cells during episodes of temporary blood loss, such as surgery or trauma.
SyntheMed, Inc. - Iselin, NJ SyntheMed, Inc. (OTCBB: SYMD) is a biomaterials company engaged in the development and commercialization of anti-adhesion and drug delivery products. The company is primarily focused on the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technology. SyntheMed's lead value driver is REPEL-CV®, a cardiac adhesion barrier film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the severity of adhesions (scar tissue). SyntheMed intends to apply its platform technology to the development of multiple products that address unmet therapeutic needs or offer improved, cost-effective alternatives to current methods of reatment. Products currently under development focus on preventing or reducing post-operative adhesions subsequent to a broad range of surgical procedures and are in various stages of clinical trials and pre-clinical studies.
Tacere Therapeutics, Inc. - San Jose, CA Tacere is an innovative biotechnology company focused on developing therapeutics to treat serious infectious diseases using its proprietary knowledge in the screening and development of both novel and traditional compounds. Its lead therapeutic compound is TT-033i, an RNA interference (RNAi) drug for the treatment of Hepatitis C. www.tacerebio.com
TransTech Pharma, Inc. - High Point, NC TransTech Pharma is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of human therapeutics to fill
unmet medical needs. The company has a pipeline of small molecule clinical
and pre-clinical drug candidates for the treatment of a wide range of human
diseases including central nervous system disorders, cardiovascular
disorders, type I/II diabetes, obesity and cancer. All of these product
candidates were developed using internal discovery and are being advanced
through in-house research and development efforts. TransTech Pharma has
strategic collaborations with leading pharmaceutical and biopharmaceutical
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
